Children
Efavirenz (Sustiva) is approved in the European Union and the United States for use in HIV-infected children aged three years and over. For children who weigh less than 40kg, dose is adjusted for weight. A syrup formulation is available for children who find capsules difficult to take.
ACTG 382 is an ongoing 48-week study of efavirenz in combination with nelfinavir (Viracept) and two nucleoside reverse transcriptase inhibitors (NRTIs) in 57 children with HIV. Results at one year showed similar safety and efficacy to adults. Rash was more common and more severe in this group than in adults, although central nervous system side-effects appear to be milder[1][2][3].
Efavirenz has not been evaluated in children under three years of age or below 13kg in weight.
latest aidsmap news
- HIV prevalence may decline because the most vulnerable are infected and die first
- Lack of perceived need for HIV treatment associated with poor adherence
- TB doesn't always increase HIV viral load
- New 75mg darunavir tablet approved by FDA for use by HIV-positive children
- Thyroid checks recommended for people with HIV
- Knighthood for head of UK HIV charity
- Gay men often not accessing PEP despite risk of HIV exposure
- Inflammatory cytokines may contribute to endothelial dysfunction in people with untreated HIV
- Internalised homophobia leads to sexual risk taking by HIV-positive gay men
- Most gay men willing to consider PrEP for possible HIV exposure